Google+ Facebook Twitter Twitter

Biomarker for genome instability

Elevated levels of a protein called ubiquilin-4 can be a biomarker for genome instability, a Tel Aviv University study shows.

The researchers found that ubiquilin-4 takes part in defending the genome from DNA damage, but too much of the protein is harmful.

When the amount of ubiquilin-4 in tumour cells rises, the cells become more prone to genome instability, accelerating the tumour’s progression and making it resistant to commonly used cancer treatments.

Professor Yossi Shiloh, who led the study, said: “This novel biomarker provides new, critical information about the tumour stage and grade, as well as the patient’s chances of responding to treatment.

“Tumours with high levels of ubiquilin-4 may be more resistant to radiation and some chemotherapies than those with normal levels of this protein. “But the good news is that they may also respond better to other types of cancer therapy.”


Related Articles


MRI for diagnosing heart disease

An international team of scientists is the first to show that magnetic resonance imaging (MRI) can be used to measure how the heart uses oxygen for both healthy patients and those with heart disease.


“More investment needed for science”

A £20bn investment is needed if the government is to achieve its vision of a science-led economy, according to a new analysis.


Synthetic DNA from extraterrestrial intelligence to future biomolecules

Following the creation of artificial E. coli, we look at the history of those pushing the boundaries in the field of synthetic biology